EcoDrugPlus

Amyloid Beta Precursor Protein

Ensembl ID : ENSELUG00000001674
Gene Symbol: APP
3 Cross references
206 Possible Orthologues:

Amyloid-Beta A4 Protein

Ensembl ID : ENSELUG00000018871
Gene Symbol: LOC105027332
3 Cross references
205 Possible Orthologues:

Androgen Receptor

Ensembl ID : ENSELUG00000010818
Gene Symbol: AR
3 Cross references
214 Possible Orthologues:

Angiotensin Ii Receptor Type 1

Ensembl ID : ENSELUG00000004016
Gene Symbol: AGTR1
3 Cross references
203 Possible Orthologues:

Angiotensin Ii Receptor Type 2

Ensembl ID : ENSELUG00000010162
Gene Symbol: AGTR2
3 Cross references
189 Possible Orthologues:

Anti-Apoptotic Protein Nr13

Ensembl ID : ENSELUG00000004478
Gene Symbol: LOC105022647
3 Cross references
129 Possible Orthologues:

Apelin Receptor B-Like

Ensembl ID : ENSELUG00000022102
Gene Symbol: LOC105017591
3 Cross references
172 Possible Orthologues:

Apurinic/apyrimidinic Endodeoxyribonuclease 1

Ensembl ID : ENSELUG00000021706
Gene Symbol: APEX1
3 Cross references
214 Possible Orthologues:

Arachidonate 5-Lipoxygenase

Ensembl ID : ENSELUG00000010507
Gene Symbol: LOC105027651
3 Cross references
191 Possible Orthologues:

Arachidonate 5-Lipoxygenase A

Ensembl ID : ENSELUG00000022892
Gene Symbol: ALOX5A
1 Cross references
213 Possible Orthologues:

Arachidonate 5-Lipoxygenase Activating Protein

Ensembl ID : ENSELUG00000007216
Gene Symbol: ALOX5AP
3 Cross references
201 Possible Orthologues:

Arg8-Vasotocin Receptor

Ensembl ID : ENSELUG00000007386
Gene Symbol: LOC105018487
4 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).